未知股票 BCLI 深 沪
等待开盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 1037.61万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasdaq to delist certain securities suspended from trading
Nasdaq (NASDAQ:NDAQ) on Wednesday announced the delisting of certain securities that were previously suspended from trading on its platform. Listed below are the securities: Digital Brands Group (DBGI...
09-24 19:58
Brainstorm Cell Q2 EPS $(0.34) Beats $(0.37) Estimate
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 43.33 percent increase over losses of $(0.60) per share from
08-14 19:07
A Peek at Brainstorm Cell's Future Earnings
Brainstorm Cell (NASDAQ:BCLI) will release its quarterly earnings report on Thu...
08-14 01:03
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
BioCardia Inc. will host a conference call on August 11, 2025, at 4:30 PM ET to discuss its Q2 2025 financial results and provide a corporate update. Participants can register via the provided link or dial-in numbers. The call will also be webcast live and available for replay afterward. BioCardia specializes in cellular therapies for cardiovascular and pulmonary diseases.
08-06 19:18
Maxim Group Downgrades Brainstorm Cell to Hold
Maxim Group analyst Jason McCarthy downgrades Brainstorm Cell (NASDAQ:BCLI) from Buy to Hold.
07-24 00:31
BrainStorm Cell Therapeutics is trading lower after receiving a delisting notice from Nasdaq effective July 18, 2025.
BrainStorm Cell Therapeutics is trading lower after receiving a delisting notic...
07-18 04:42
Brainstorm Cell Therapeutics Files Prospectus For Offer & Sale Of Up To 2.8M Shares Of Common Stock By Selling Stockholder
https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm
06-26 04:47
BrainStorm Announces New Survival Data From Expanded Access Program Of NurOwn In ALS; 90% Of Participants Survived More Than Five Yers From Onset Of ALS Symptoms
Key findings include:90% of participants (9/10) survived more than five years from the onset of ALS symptoms, compared to published estimates indicating that approximately 10% of individuals with ALS survive beyond five
06-16 20:31
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Longevity Health Holdings (NASDAQ:XAGE) shares moved upwards by 55.5% ...
05-22 05:06
Brainstorm Cell Therapeutics Reports Q1 2025 Financials
Brainstorm Cell Therapeutics ( ($BCLI) ) has released its Q1 earnings. Here is ...
05-20 11:54
